Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LaFleur Minerals Announces MOU with Granada Gold on Milling Assessment (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its... see more

Recent & Breaking News (NDAQ:GILD)

Gilead Sciences to Release First Quarter 2013 Financial Results on Thursday, May 2, 2013

Business Wire April 25, 2013

StockCall Study on Gilead Sciences, NPS Pharma, InterMune, Seattle Genetics, and Halozyme Therapeutics

ACCESS Newswire April 24, 2013

Data from Phase 3 studies of Gilead's sofosbuvir for hepatitis C to be presented at 48th Annual EASL Meeting; Findings published online today in The New England Journal of Medicine

Canada NewsWire April 23, 2013

Netflix Indicating Big Jump Pre-Market on Earnings Surprise - Top Earnings Stocks Ahead of the Bell: Power-One Inc., Goff Corporation, AMR Corporation, Fannie Mae, Vertex Pharmaceuticals

PR Newswire April 23, 2013

Data from Phase 3 Studies of Gilead's Sofosbuvir for Hepatitis C

Business Wire April 23, 2013

Cheaper Gas, Airfare, Profits on Way as Commodities Slump Continues? - Top Small Cap Stock Focus Ahead of the Bell:

PR Newswire April 22, 2013

Perfect Trade Setups, How to Play AMGN, GILD, JCP and PCLN

Marketwired April 15, 2013

What's Going On: Eco Trade Corp, Merck & Co, Gilead Sciences, Yahoo! Inc

ACCESS Newswire April 12, 2013

The Real Story Behind JNJ, GILD, WMT and CMCSA

Marketwired April 12, 2013

Gilead Sciences Inc. And Pfizer Inc. Announcements: (NASDAQ: GILD), (NYSE: PFE)

ACCESS Newswire April 12, 2013

Perfect Trade Setups, How to Play GILD, TWX, BA and HD

Marketwired April 10, 2013

Start Making Profits Now With BA, GILD, MET and PG

Marketwired April 9, 2013

Gilead Submits New Drug Application to U.S. FDA for Sofosbuvir for the Treatment of Hepatitis C

Business Wire April 8, 2013

Start Making Profits Now With GE, CMCSA, GILD and GS

Marketwired April 8, 2013

Special Offer for Shareholders of QCOM, AMZN, GS and GILD

Marketwired April 8, 2013

Before the Crowd, How We Found VRX, MCD, VALE and GILD

Marketwired April 5, 2013

Secrets to Making Money in NFLX, VLO and GILD

Marketwired April 4, 2013

S&P 500 Climbs to New Record and EBay to Handle $110 Billion of Marketplace Volume in 2015

PR Newswire April 1, 2013

Strategy Behind Our Success, We Get in Early: GS, IBM, GE and GILD

Marketwired April 1, 2013

Traders' Favorite: Gilead Sciences, J.C. Penney Company, SK3 Group

ACCESS Newswire March 27, 2013